Healthcare / Drug Manufacturers - GeneralUpdated 2026-05-10 22:07 UTC

NSRX stock hub

Nasus Pharma Ltd. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

NSRXis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

36.9M

NYSEAMERICAN

Market data

Live price

Current market quote for this ticker.

Current price

NSRX

In the news

Latest news · NSRX

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROEn/a

P25 -105.6P50 -46.5P75 -3.1

ROIC-415.3

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All NSRX market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

157

Groups with data

Currency

USD

Showing 157 of 157 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0002029039
Company name	Nasus Pharma Ltd.
Country	Israel
Country code	US
Cusip	001218155
Employees	7
Employees Change	5%
Employees Change Percent	250
Enterprise value	$32.7M
Exchange	NYSEAMERICAN
Financial currency	USD
First seen	2026-05-09
Industry	Drug Manufacturers - General
IPO Date	2025-08-14
Isin	IL0012181553
Last refreshed	2026-05-10
Market cap	$36.9M
Market cap category	Nano-Cap
Price	$3.15
Price currency	USD
Sector	Healthcare
Sic	2834
Symbol	NSRX
Website	https://www.nasuspharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-15.87%
FCF yield	-13.37%
P/B ratio	10.26x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-5.9M
Net Income Growth Years	0%
Profit Per Employee	$-836,571
ROA	-107.1
ROCE	-172.6
ROIC	-415.3

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS Growth Years	0
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$5M
Cash	$4.3M
Current Assets	$4.9M
Current Liabilities	$2.2M
Debt	$118,000
Debt Equity	$0.04
Equity	$2.8M
Liabilities	$2.2M
Long Term Assets	$149,000
Long Term Liabilities	$73,000
Net Cash	$4.2M
Net Cash By Market Cap	$11.3
Net Debt Equity	$-1.51
Tangible Book Value	$2.8M
Tangible Book Value Per Share	$0.31

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	2.24
Net Working Capital	$-1.5M
Quick ratio	1.98
Working Capital	$2.7M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-15.11%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
50-day SMA	3.12
All Time High	9.99
All Time High Change	-68.47%
All Time High Date	2025-08-22
All Time Low	1.98
All Time Low Change	59.09%
All Time Low Date	2026-03-31
ATR	0.41
Beta1y	0.97
Ch YTD	-65.57
High	3.39
High52	9.99
High52 Date	2025-08-22
High52ch	-68.47%
Low	2.95
Low52	1.98
Low52 Date	2026-03-31
Low52ch	59.09%
Ma50ch	0.9%
Premarket Change Percent	-1.18
Premarket Price	$3.35
Premarket Volume	1,510
RSI	52.74
RSI Monthly	0
RSI Weekly	34.74
Sharpe ratio	-0.64x
Sortino ratio	-0.83
Total Return	-15.11%
Tr YTD	-65.57
Tr1m	39.38%
Tr1w	14.55%
Tr3m	-42.1%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	3
Analyst Count Top	2
Analyst Price Target Top	$18.5
Analyst Ratings	Strong Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$-0.19
Operating Income	$-4.9M
Price target	$19.67
Price Target Change	$524
Price Target Change Top	$487

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	5,495,825%
Float Percent	46.93%
Shares Insiders	34.17%
Shares Institutions	5.32%
Shares Out	11,710,808
Shares Yo Y	15.11%
Short Float	1.18%
Short Ratio	0.14
Short Shares	0.55

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-5.4M
Average Volume	138,214.6x
Bv Per Share	0.31
CAPEX	$-14,000
Ch1m	39.38
Ch1w	14.55
Ch3m	-42.1
Ch6m	-58
Change	-7.08%
Change From Open	-6.53
Close	3.39
Days Gap	-0.59
Dollar Volume	331,524.9
Earnings Date	2026-03-25
Earnings Time	bmo
EBIT	$-4.9M
EPS	$-0.73
F Score	2
FCF	$-4.9M
FCF EV Yield	-15.07x
FCF Per Share	$-0.42
Financing CF	8,920,000
Fiscal Year End	December
Founded	2,019
Investing CF	-3,014,000
Ipr	-60.63
Iprfo	-64.2
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-03-25
Last Report Date	2025-12-31
Last Split Type	Never
Last10k Filing Date	2026-03-25
Ma150	5.69
Ma150ch	-44.64%
Ma20	2.88
Ma20ch	9.41%
Net CF	980,000
Next Earnings Date	2026-12-29
Open	3.37
Optionable	No
Position In Range	46.07
Ppne	149,000
Pre Close	3.39
Price Date	2026-05-08
Ptbv Ratio	13.33
Relative Volume	0.76x
Share Based Comp	447,000
Tr6m	-58%
Volume	105,246

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does NSRX pay a dividend?

Capital-return profile for this ticker.

Ownership

Who owns NSRX?

Insider, institutional, and short-interest positioning.

Institutional ownership

+5.3%

Float: +46.9% of shares outstanding

Insider ownership

+34.2%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

NSRX momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

52.7

Neutral momentum band

Price vs 200-day MA

n/a

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

-0.64

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About NSRX

Hub-level FAQ points readers to the deeper analysis pages.

What is the current NSRX stock rating?

Nasus Pharma Ltd. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full NSRX analysis?

The full report lives at /stocks/NSRX/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for NSRX?

The latest report frames NSRX around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the NSRX page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.